Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Net Income (2016 - 2025)

Historic Net Income for Neuroone Medical Technologies (NMTC) over the last 13 years, with Q4 2025 value amounting to -$1.4 million.

  • Neuroone Medical Technologies' Net Income fell 18053.95% to -$1.4 million in Q4 2025 from the same period last year, while for Dec 2025 it was -$6.8 million, marking a year-over-year increase of 499.87%. This contributed to the annual value of -$3.6 million for FY2025, which is 7073.11% up from last year.
  • Neuroone Medical Technologies' Net Income amounted to -$1.4 million in Q4 2025, which was down 18053.95% from -$1.6 million recorded in Q3 2025.
  • In the past 5 years, Neuroone Medical Technologies' Net Income registered a high of $1.8 million during Q4 2024, and its lowest value of -$3.5 million during Q1 2023.
  • Over the past 5 years, Neuroone Medical Technologies' median Net Income value was -$2.8 million (recorded in 2022), while the average stood at -$2.4 million.
  • As far as peak fluctuations go, Neuroone Medical Technologies' Net Income soared by 15337.45% in 2024, and later crashed by 18053.95% in 2025.
  • Neuroone Medical Technologies' Net Income (Quarter) stood at -$2.8 million in 2021, then soared by 38.28% to -$1.7 million in 2022, then plummeted by 93.04% to -$3.3 million in 2023, then skyrocketed by 153.37% to $1.8 million in 2024, then plummeted by 180.54% to -$1.4 million in 2025.
  • Its Net Income stands at -$1.4 million for Q4 2025, versus -$1.6 million for Q3 2025 and -$1.5 million for Q2 2025.